PMID- 33076798
OWN - NLM
STAT- MEDLINE
DCOM- 20210426
LR  - 20210426
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 27
IP  - 5
DP  - 2021
TI  - Neuroprotective and Preventative Effects of Molecular Hydrogen.
PG  - 585-591
LID - 10.2174/1381612826666201019103020 [doi]
AB  - One of the beneficial effects of molecular hydrogen (H(2), hydrogen gas) is 
      neuroprotection and prevention of neurological disorders. It is important and 
      useful if taking H(2) every day can prevent or ameliorate the progression of 
      neurodegenerative disorders, such as Parkinson's disease or Alzheimer's disease, 
      both lacking specific therapeutic drugs. There are several mechanisms of how H(2) 
      protects neuronal damage. Anti-oxidative, anti-inflammatory, and the regulation 
      of the endocrine system via stomach-brain connection seem to play an important 
      role. At the cellular and tissue level, H(2) appears to prevent the production of 
      reactive oxygen species (ROS), and not only hydroxy radical (*OH) but also 
      superoxide. In Parkinson's disease model mice, chronic intake of H(2) causes the 
      release of ghrelin from the stomach. In Alzheimer's disease model mice, 
      sex-different neuroprotection is observed by chronic intake of H(2). In female 
      mice, declines of estrogen and estrogen receptor-beta (ERbeta) are prevented by H(2), 
      upregulating brain-derived neurotrophic factor (BDNF) and its receptor, tyrosine 
      kinase receptor B (TrkB). The question of how drinking H(2) upregulates the 
      release of ghrelin or attenuates the decline of estrogen remains to be 
      investigated and the mechanism of how H(2) modulates endocrine systems and the 
      fundamental question of what or where is the target of H(2) needs to be 
      elucidated for a better understanding of the effects of H(2).
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Noda, Mami
AU  - Noda M
AD  - Laboratory of Pathophysiology, Graduate School of Pharmaceutical Sciences, Kyushu 
      University, Fukuoka 812-8582, Japan.
FAU - Liu, Jiankang
AU  - Liu J
AD  - Center for Mitochondrial Biology and Medicine and Center for Translational 
      Medicine, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an 
      710049, China.
FAU - Long, Jiangang
AU  - Long J
AD  - Center for Mitochondrial Biology and Medicine and Center for Translational 
      Medicine, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an 
      710049, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Reactive Oxygen Species)
RN  - 7YNJ3PO35Z (Hydrogen)
SB  - IM
MH  - Animals
MH  - Female
MH  - Hydrogen
MH  - Mice
MH  - *Neurodegenerative Diseases
MH  - Neuroprotection
MH  - *Neuroprotective Agents/pharmacology
MH  - Oxidative Stress
MH  - Reactive Oxygen Species
OTO - NOTNLM
OT  - Hydrogen gas
OT  - anti-oxidant
OT  - estrogen
OT  - ghrelin
OT  - neuroprotection
OT  - sex-difference
EDAT- 2020/10/21 06:00
MHDA- 2021/04/27 06:00
CRDT- 2020/10/20 05:39
PHST- 2020/04/26 00:00 [received]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/04/27 06:00 [medline]
PHST- 2020/10/20 05:39 [entrez]
AID - CPD-EPUB-110729 [pii]
AID - 10.2174/1381612826666201019103020 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2021;27(5):585-591. doi: 10.2174/1381612826666201019103020.